Rare diseases
2nd Integrin-Targeted Drug Development Summit
Erin Thomas
autoimmune, integrin, ophthalmology, Rare diseases
0 Comment
Rare diseases have tenfold higher impact on healthcare costs; study
Phil Taylor
Chiesi, IQVIA, Rare Disease Day, Rare diseases
0 Comment
R&D/ Views & Analysis/ Views and analysis
Rare Disease R&D: one step forward, but a long road ahead
Ben Hargreaves
Rare Disease Day, rare disease R&D, Rare diseases
0 Comment
Orphazyme ‘looking at options’ after lead drug hits buffers in EU
Phil Taylor
Niemann-Pick type C, Orphazyme, Rare diseases
0 Comment
Real-World Evidence 2022: Rare Diseases and Innovative Therapies
Darcy Hodge
digital health, patient centricity, pharma, Rare diseases, Real World Evidence
0 Comment
RWE Live convenes those involved in RWE, HTA and more.
2nd Mitochondria-Targeted Drug Development Summit
jenna.warren@hansonwade.com
drug development, Mitochondria, Mitochondrial Dysfunction, neurodegenerative, Rare diseases
0 Comment
Therapies for mitochondrial dysfunction
R&D/ Views & Analysis/ Views and analysis/ Webinars/ Webinars in home page/ Webinars On demand
The power of R&D collaborations to improve outcomes in rare diseases
mike.hammerton@pharmaphorum.com
genomic medicine, IQVIA, orphan drugs, precision medicine, Rare diseases
0 Comment
Sales and Marketing/ Views & Analysis/ Views and analysis
The benefits of being a family-run pharma company
mike.hammerton@pharmaphorum.com
Chiesi, Rare diseases
0 Comment